Matt Shanahan
Ceist:694. Deputy Matt Shanahan asked the Minister for Health the downstream and overall cost-benefit analysis conducted by the corporate pharmaceutical unit when assessing reimbursement applications for novel and generic drug applications; his views on whether the full system savings are being considered in such applications; if evidence of same in action can be demonstrated; and if he will make a statement on the matter. [39906/20]
Amharc ar fhreagra